Pure MHC, LLC and AbbVie will embark on a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers. The collaboration between AbbVie and Pure MHC will seek to identify a library of peptide targets for further research across multiple tumor types and advance AbbVie’s ongoing development of next-generation immuno-oncology therapies.